We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App





Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Print article
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.